Document is current
Any future updates will be listed below
-
Authors
Celay, Jon
Recalde, Miriam
Revuelta, Maria V.
Larrayoz, Marta
Vicente, Carmen
Lozano, Teresa
Gil, Carmen
Chapman, Jennifer R.
Garcia-Lacarte, Marcos
Gonzalez, Carmen
Ariceta, Beñat
Rodriguez, Sara
Lasa, Marta
Garcia-Barchino, Maria J.
Fresquet, Vicente
Jimenez, Maddalen
Sanz, Sonia
Du, Ming-Qing
Roncador, Giovanna
Vega, Zaira
Sacco, Antonio
Roccaro, Aldo
Knittel, Gero
Reinhardt, Hans Christian
Piazza, Rocco
Herter, Sylvia
Goodhew, Rebecca
Caron, Jonathan
Roos-Weil, Damien
Miguel, Jesus San
Canales, Miguel
Hodson, Daniel J.
Lossos, Izidore S.
Lasarte, Juan J.
Roa, Sergio
Prosper, Felipe
Paiva, Bruno
Cerchietti, Leandro
Martinez-Climent, Jose A.
- License Information
-
More Information
Article History
Received: 8 September 2025
Accepted: 13 March 2026
First Online: 20 April 2026
Declarations
:
: All research involving human samples, data, and patients has been performed in accordance with the Declaration of Helsinki, has been approved by the corresponding ethical committees, and has been performed in accordance with the regulations of the corresponding Institutional Review Boards of the different institutions. Informed consent was obtained from patients, as detailed in the Materials and Methods section.Animal experimentation has been approved by the Ethical Committee of Animal Experimentation of the University of Navarra and by the Health Department of the Navarra Government, as detailed in the Materials and Methods section.For all research involving patients, informed consent to participate in the study has been obtained from all participants.
: Not applicable.
: S.H. is an employee of F. Hoffmann-La Roche Ltd. and holds ownership of Roche stocks and patents.H.C.R. has received consulting and lecture fees from Abbvie, AstraZeneca, Vertex and Merck and research funding from AstraZeneca and Gilead Pharmaceuticals, and is co-founder of CDL Therapeutics GmbH.J.A.M.-C. has received research funding from Roche-Genentech, Bristol Myers Squibb, Janssen, Regeneron, Priothera Pharmaceuticals, Palleon Pharmaceuticals, AstraZeneca, and K36 Therapeutics, and is founder and holds stock options of MIMO Biosciences. The remaining authors have nothing to declare.
